Search

Your search keyword '"OVERALL survival"' showing total 16 results
16 results on '"OVERALL survival"'

1. 18-Month Survival Results of Neoadjuvant Cemiplimab in Advanced Resectable CSCC May Lead to Reconsideration of Adjuvant Treatment.

Author

Joszt, Laura

Subjects
*DRUG efficacy, *IMMUNE checkpoint inhibitors, *CANCER relapse, *SKIN tumors, *COMBINED modality therapy, *SQUAMOUS cell carcinoma, *PREANESTHETIC medication, *OVERALL survival
Abstract

The article reports on the results of a phase 2 trial on the use of the neoadjuvant cemplimab in treating patients with resectable stage II to stage IV cutaneous squamous cell carcinoma (CSCC). According to Doctor Neil D. Gross of the University of Texas MD Anderson Cancer Center, the drug showed favorable survival results in patients with 51% of them showing pathologic complete response (pCR) rate per central review.

Published
2023

2. Impactful Studies Challenge the Status Quo at GI Conference.

Author

Berberabe, Tony

Subjects
GASTROINTESTINAL tumors, MEDICAL quality control, CLINICAL trials, CANCER patient medical care, ENDOTHELIAL growth factors, IMMUNOTHERAPY, CONFERENCES & conventions, COLORECTAL cancer, IMMUNE checkpoint inhibitors, PANCREATIC tumors, MONOCLONAL antibodies, DUCTAL carcinoma, DRUG efficacy, PROGRESSION-free survival, ONCOLOGISTS, HEALTH care teams, SEQUENCE analysis, OVERALL survival
Published
2024

3. The Benefits of Elacestrant in HR+/HER2– Metastatic Breast Cancer Subgroups.

Author

Kaklamani, Virginia G.

Subjects
LIVER disease diagnosis, BREAST cancer diagnosis, SENTINEL lymph node biopsy, DOCETAXEL, AROMATASE inhibitors, PROTEIN kinase inhibitors, HORMONE receptor positive breast cancer, PATIENT safety, COMPUTED tomography, CYSTS (Pathology), DECISION making in clinical medicine, METASTASIS, ESTROGEN receptors, ADJUVANT chemotherapy, DUCTAL carcinoma, ONCOGENES, NEEDLE biopsy, DRUG efficacy, QUALITY of life, GENETIC mutation, LUMPECTOMY, CYCLOPHOSPHAMIDE, OVERALL survival
Published
2024

4. Clinical Updates: BLADDER CANCER. Adding durvalumab to chemotherapy extends survival in MIBC.

Author

CLARKE, HANNAH

Subjects
*PREVENTION of drug side effects, *THERAPEUTIC use of monoclonal antibodies, *CANCER relapse, *PATIENT safety, *INVESTIGATIONAL drugs, *TERMINATION of treatment, *CLINICAL trials, *CANCER chemotherapy, *METASTASIS, *DRUG approval, *ENDOMETRIAL tumors, *COMBINED modality therapy, *DRUG efficacy, *PROGRESSION-free survival, *LUNG cancer, *OVERALL survival, *DISEASE progression, *HEPATOCELLULAR carcinoma, TUMOR surgery, BLADDER tumors, BILE duct tumors
Abstract

The article focuses on a news release from AstraZeneca on the results of the phase three NIAGARA trial, which shows the effectiveness of the combination of durvalumab and chemotherapy in improving event-free survival and overall survival in patients with muscle-invasive bladder cancer. Topics discussed include the safety of durvalumab in the trial, and the selection of the participants.

Published
2024

5. Paclitaxel/Ramucirumab Prolongs Survival in Gastric Cancer.

Author

Bayer, Morgan

Subjects
THERAPEUTIC use of antineoplastic agents, THERAPEUTIC use of antimetabolites, THERAPEUTIC use of monoclonal antibodies, PLATINUM compounds, STOMACH tumors, DRUG side effects, PATIENT safety, IMMUNOTHERAPY, TREATMENT effectiveness, CANCER chemotherapy, COMBINED modality therapy, DRUG efficacy, PACLITAXEL, PROGRESSION-free survival, OVERALL survival, BIOMARKERS, EVALUATION
Published
2024

6. Nogapendekin alfa inbakicept-pmln (N-803; Anktiva).

Subjects
NON-muscle invasive bladder cancer, COMBINATION drug therapy, BLADDER tumors, MYCOBACTERIUM, PATIENT safety, DRUG approval, DRUG efficacy, PROGRESSION-free survival, CELL receptors, CARCINOMA in situ, OVERALL survival, THERAPEUTICS
Published
2024

7. Linvoseltamab Delivers Deep, Durable Responses in R/R Multiple Myeloma.

Author

Rosa, Kristi

Subjects
THERAPEUTIC use of monoclonal antibodies, MULTIPLE myeloma, RISK assessment, SYNDROMES, PATIENT safety, DRUG side effects, NEUROTOXICOLOGY, DRUG administration, MONOCLONAL antibodies, DRUG efficacy, DISEASE relapse, PROGRESSION-free survival, PATIENT aftercare, OVERALL survival, EVALUATION, DISEASE risk factors
Published
2024

8. FDA Grants Full Approval to Elahere.

Subjects
THERAPEUTIC use of antineoplastic agents, FOLIC acid metabolism, THERAPEUTIC use of monoclonal antibodies, WOMEN, COST effectiveness, ANTINEOPLASTIC agents, OVARIAN tumors, CANCER patients, EYE care, DRUG approval, PHARMACY information services, MONOCLONAL antibodies, DRUG monitoring, DRUG efficacy, FALLOPIAN tube diseases, OVARIAN epithelial cancer, PERITONEUM tumors, PROGRESSION-free survival, CELL receptors, OVERALL survival, DRUG labeling
Abstract

The article focuses on the U.S. Food and Drug Administration (FDA) has approved Elahere for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients with prior systemic treatment. It reports that the approval was based on data from the confirmatory phase 3 MIRASOL trial, showing a reduction in death and cancer progression risk. Elahere, developed by ImmunoGen and acquired by AbbVie, targets folate receptor alpha.

Published
2024

10. Amivantamab-vmjw (Rybrevant).

Subjects
THERAPEUTIC use of antineoplastic agents, THERAPEUTIC use of monoclonal antibodies, PEMETREXED, CARBOPLATIN, DRUG approval, METASTASIS, MONOCLONAL antibodies, DRUG efficacy, LUNG cancer, GENETIC mutation, PROGRESSION-free survival, EPIDERMAL growth factor receptors, OVERALL survival
Published
2024

11. Lifileucel Shows Long-Term Efficacy in Melanoma.

Author

Flaherty, Courtney

Subjects
MELANOMA treatment, T cells, IMMUNOTHERAPY, CELLULAR therapy, CONFERENCES & conventions, ONCOLOGY, TREATMENT effectiveness, DESCRIPTIVE statistics, DRUG approval, DRUG efficacy, OVERALL survival, EVALUATION
Published
2024

12. Pembrolizumab/axitinib sustains efficacy in ccRCC at 5-year follow-up.

Author

ROSA, KRISTI

Subjects
*THERAPEUTIC use of antineoplastic agents, *RENAL cell carcinoma, *DRUG efficacy, *PATIENT aftercare, *COMBINATION drug therapy, *COLLEGE teacher attitudes, *TREATMENT effectiveness, *BENZAMIDE, *PROGRESSION-free survival, *OVERALL survival, *THERAPEUTICS
Abstract

The article discusses results from an analysis of the phase three KEYNOTE-426 trial on the efficacy of a combination treatment with pembrolizumab and axitinib, compared with single agent sunitinib, in patients with clear cell renal cell carcinoma (CCRCC). The study evaluated overall survival, progression-free survival, overall response rate, complete response rate, partial response rare, stable disease rate in patients who received pembrolizumab/axitinib and those administered with sunitinib.

Published
2023

13. Orca-T Use Demonstrates Promise for Patients With Hematologic Malignant Tumors.

Author

Seymour, Caroline

Subjects
THERAPEUTIC use of antineoplastic agents, GRAFT versus host disease prevention, HEMATOPOIETIC stem cell transplantation, HEMATOLOGIC malignancies, PATIENT safety, COMPLICATIONS of prosthesis, HOMOGRAFTS, TREATMENT effectiveness, AGE distribution, DRUG efficacy, PROGRESSION-free survival, OVERALL survival
Published
2024

15. Lenvatinib Is Effective, Regardless of Age in HCC.

Author

Berberabe, Tony

Subjects
THERAPEUTIC use of antineoplastic agents, PATIENT safety, FATIGUE (Physiology), TREATMENT effectiveness, DRUG efficacy, PROGRESSION-free survival, HEPATOCELLULAR carcinoma, OVERALL survival, OLD age
Published
2024

16. Ponatinib (Iclusig).

Subjects
LYMPHOBLASTIC leukemia prognosis, THERAPEUTIC use of antineoplastic agents, PROTEIN-tyrosine kinase inhibitors, CANCER chemotherapy, DRUG approval, DRUG efficacy, COMBINED modality therapy, LYMPHOBLASTIC leukemia, PROGRESSION-free survival, OVERALL survival
Published
2024

Catalog

Books, media, physical & digital resources
See catalog results